

Torrent Pharmaceuticals Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialize its Novel Gastrointestinal Drug in India

Ahmedabad, India 05th June 2024: Torrent Pharmaceuticals Limited (Torrent) today announced that it has entered into a non-exclusive patent licensing agreement with Takeda to commercialize Vonoprazan in India. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of acid related disorders - Gastroesophageal Reflux Disease (GERD). Torrent will market Vonoprazan under its own trademark, Kabvie.

As per a 2019 study published by Indian Journal of Gastroenterology prevalence of GERD in Indian population is around 8.2%, with a higher prevalence of around 11.1% in urban population. According to AWACS MAT April 2024 data, the Indian market for treatments used in GERD is valued at INR 8,064 crore, growing at 8% CAGR over the last 4 years. Currently treatments such as Pantoprazole (Proton Pump Inhibitors) are used to treat GERD. Availability of P-CABs such as Kabvie will make accessible new and effective treatments of GERD for the Indian population.

Commenting on the agreement, Aman Mehta – Director, Torrent said, “We are delighted to commercialize this novel treatment for Indian patients. I am confident that the launch of Kabvie will aid in reducing the disease burden of GERD and further strengthen our Gastrointestinal offerings, augmenting our position as a leading player within the Indian Pharmaceutical Market.”

About Torrent Pharmaceuticals Ltd:

Torrent Pharma, with annual revenue of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenue of more than Rs 40,000 crores. It is ranked 5th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastrointestinal (GI), Central Nervous System (CNS), and Vitamins Minerals Nutritional (VMN).

It is a specialty-focused company with 74%+ of its revenue in India from chronic & sub-chronic therapies. It has presence in 50 countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil, Germany and Philippines. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 750+ scientists.

In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone : +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com